Key Points
- Merck EVP Chirfi Guindo sold 15,000 shares at an average price of $131, generating $1.965 million and reducing his direct ownership by 24.35% to 46,613 shares.
- Merck reported quarterly revenue of $16.61 billion, exceeding estimates, while adjusted earnings per share also beat expectations; revenue increased 5.1% year over year.
- The company declared a quarterly dividend of $0.85 per share, equivalent to $3.40 annually and a 2.6% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $134.56.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) EVP Chirfi Guindo sold 15,000 shares of the firm's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the transaction, the executive vice president directly owned 46,613 shares in the company, valued at approximately $6,106,303. This represents a 24.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Merck & Co., Inc. Trading Up 0.2%
Shares of MRK opened at $128.61 on Friday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $135.05. The firm has a 50 day moving average price of $123.98 and a 200-day moving average price of $119.11. The firm has a market cap of $317.64 billion, a price-to-earnings ratio of 102.89, a PEG ratio of 5.53 and a beta of 0.19.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the previous year, the firm posted $2.13 earnings per share. The firm's revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts forecast that Merck & Co., Inc. will post 2.77 earnings per share for the current year.
Merck & Co., Inc. Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.'s payout ratio is presently 272.00%.
More Merck & Co., Inc. News
Here are the key news stories impacting Merck & Co., Inc. this week:
- Positive Sentiment: Recent approvals and label-expansion efforts for KEYTRUDA and ENFLONSIA, together with Merck’s raised 2026 revenue outlook, are reinforcing the investment case. One analysis estimates the shares may still be modestly undervalued after a strong recent run. Merck Could Be Undervalued on Raised Outlook and Approvals
- Positive Sentiment: Positive cancer-drug trial readouts and broader strength across biotechnology and pharmaceutical stocks could support investor interest in Merck’s oncology portfolio and pipeline. These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
- Neutral Sentiment: An industry report identifies continued opportunities in endometrial cancer, including frontline immunotherapy combinations, companion diagnostics and precision therapies. The report highlights Merck as a participant but does not announce a new company-specific deal or result. Endometrial Cancer Market Share Analysis and Industry Trends
- Negative Sentiment: Three Merck executive vice presidents reported selling a combined 86,553 shares for approximately $11.2 million. The transactions reduced their individual holdings by roughly 24% to 62%, which may weigh on sentiment, although insider sales do not necessarily indicate a change in company fundamentals. Chirfi Guindo SEC Form 4 David Michael Williams SEC Form 4 David R. Maraldo SEC Form 4
- Negative Sentiment: Merck is working to diversify beyond KEYTRUDA ahead of its expected 2028 patent expiration. The need for acquisitions, partnerships and new growth platforms underscores the long-term revenue risk associated with the company’s largest product. Merck Is Racing Beyond KEYTRUDA
Analyst Ratings Changes
A number of analysts have recently weighed in on the stock. CICC Research assumed coverage on shares of Merck & Co., Inc. in a report on Wednesday, June 24th. They set an "outperform" rating and a $138.00 target price for the company. Wells Fargo & Company boosted their price target on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an "overweight" rating in a report on Wednesday, July 8th. Barclays upped their price target on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Guggenheim increased their price objective on Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Weiss Ratings lowered Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a research report on Friday, May 15th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $134.56.
Read Our Latest Analysis on Merck & Co., Inc.
Institutional Trading of Merck & Co., Inc.
Several large investors have recently bought and sold shares of the company. Kingdom Financial Group LLC. purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $25,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc purchased a new stake in Merck & Co., Inc. in the fourth quarter worth $26,000. High Note Wealth LLC grew its stake in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after purchasing an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. in the fourth quarter worth $31,000. 76.07% of the stock is owned by institutional investors.
Merck & Co., Inc. Company Profile
(
Get Free Report)
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
